Aleta Biotherapeutics

Executive Summary

Aleta Biotherapeutics is a clinical-stage biotechnology company developing CAR T Engager (CTE) biologics designed to enhance the efficacy of existing CAR T-cell therapies. Its lead program targets B-cell lymphoma patients who have relapsed after CD19 CAR T therapy and is currently in Phase I/II trials. The CTE platform aims to overcome key limitations of CAR T therapy, including antigen escape and limited persistence. By bridging endogenous T cells or infused CAR T cells to tumor cells, Aleta's approach has the potential to improve outcomes in refractory patients. The company is privately held and based in Waltham, Massachusetts.

Upcoming Catalysts (preview)

• Q2 2026Phase I/II interim data readout for lead CTE program in relapsed B-cell lymphoma40% success
• Q4 2026Potential partnership or licensing deal for CTE platform35% success
• Q1 2027Initiation of Phase I trial for next-generation CTE candidate50% success